Month: May 2024

Participants Are Welcome to Listen June 3rd at 9:00 am ET Waltham, Mass., May 13, 2024 (GLOBE NEWSWIRE) — Nano Dimension Ltd. (Nasdaq: NNDM, “Nano Dimension” or the “Company”), a leading supplier of Additively Manufactured Electronics (“AME”) and multi-dimensional polymer, metal & ceramic Additive Manufacturing (“AM”) 3D printers, announced today that it will release its financial results for the first quarter of 2024 before the Nasdaq market opens on Monday, June 3rd, 2024. Mr. Yoav Stern, Chief Executive Officer and Member of the Board of Directors, Mr. Tomer Pinchas, Chief Financial Officer & Chief Operating Officer, and Mr. Julien Lederman, VP of Corporate Development, of Nano Dimension will host a conference call on June 3rd, 2024, at 9:00 a.m. ET, to discuss the financial results. Participants can register for...

Received FDA Fast Track Designation for the investigation of CTX-009 in combination with paclitaxel for the treatment of patients with metastatic or locally advanced biliary tract tumors.Enrollment is progressing well in COMPANION-002, a Phase 2/3 randomized study of CTX-009 (DLL4 x VEGF-A bispecific antibody) in patients with advanced biliary tract cancer (BTC). Enrollment is expected to be completed by mid-year 2024 with top-line data expected in the first quarter of 2025. Completed enrollment of patients in COMPANION-003, a Phase 2 study of CTX-009 in patients with advanced colorectal cancer (CRC); top-line data from Stage 1 are expected by mid-year 2024. Enrollment in the Phase 1b combination study of CTX-471 (CD137 agonist antibody) and KEYTRUDA® in patients with non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC)...

First Quarter Highlights ●  Revenue of $40.4 million, down 5.7% year-over-year (7.3% on a constant currency basis)●  Gross margin grew to 24.6%, a 270 bps increase sequentially and 250 bps increase year-over-year●  Net loss of $2.2 million includes $0.8 million of FX losses       ●  High margin Technology segment grew to 28.4% of revenues, a 120 bps increase sequentially and 690 bps increase year-over-year●  Awarded a multi-year contract with His Majesty’s Passport Office (“HMPO”) for a nationwide project in the UK with a Total Contract Value (“TCV”) of approximately $40 million LONDON and SANTA MONICA, Calif., May 13, 2024 (GLOBE NEWSWIRE) — XBP Europe Holdings, Inc. (“XBP Europe” or the “Company”) (NASDAQ: XBP), a pan-European integrator of bills, payments, and related solutions and services seeking to enable the digital transformation...

HALIFAX, Nova Scotia, May 13, 2024 (GLOBE NEWSWIRE) — Erdene Resource Development Corp. (TSX:ERD; MSE:ERDN) (“Erdene” or the “Company”) is pleased to announce operating and financial results for the three months ended March 31, 2024, and to provide an update on progress at its Bayan Khundii Gold Project (“BK” or “Project”), being developed with Mongolian Mining Corporation (“MMC”). This release should be read in conjunction with the Company’s Q1-2024 Condensed Consolidated Interim Financial Statements and MD&A, available on the Company’s website and SEDAR+. Peter Akerley, Erdene’s President and CEO stated, “During the first quarter, Erdene and MMC closed their Strategic Alliance and formally launched construction of the Bayan Khundii Gold Project, one of the highest grade, open pit gold mines under...

SOLANA BEACH, Calif., May 13, 2024 (GLOBE NEWSWIRE) —  Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic and neurological conditions, today reported financial and operating results for the three months ended March 31, 2024 and provided a business update. “Our entire clinical and preclinical development portfolio is progressing as planned,” commented Gregory D. Gorgas, President and Chief Executive Officer of Artelo Biosciences. “Significantly, our Investigational New Drug (IND) application to the U.S. Food and Drug Administration for ART26.12, our lead Fatty Acid Binding Protein 5 (FABP5) inhibitor for the treatment of neuropathic pain, is in the final stages of preparation.” ART26.12...

CARLSBAD, Calif., May 13, 2024 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended March 31, 2024. First Quarter Highlights:Recognized total revenue of $14.4 million in the first quarter of 2024, a 28.4% increase over the first quarter of 2023. Delivered gross margin of 59.6% in the first quarter of 2024, compared to a gross margin of 47.2% in the first quarter of 2023.AVISE® CTD trailing twelve-month average selling price (ASP) of $377, a 35.1% increase over the trailing twelve-month ASP in the first quarter of 2023.Net loss of $3.4 million in the first quarter of 2024, a 56.3% improvement over the first quarter of 2023.Adjusted EBITDA of $(2.0) million for the first quarter of 2024, a 67.7% improvement over the first...